IDT Biologika, a contract development and manufacturing organization (CDMO) specializing in vaccines, gene and immune therapy, and oncolytic viruses, and Exothera, a CDMO specializing in the industrialization of vaccine and gene therapy processes, announced on March 1, 2022 that they have formed a collaboration to develop a large-scale manufacturing process for viral vector-based vaccines. The feasibility study they will conduct will focus on Modified Vaccinia Ankara (MVA) virus as the first target for IDT’s vector technologies.
Exothera has done a successful transfer of IDT Biologika’s upstream process from small-scale to large-scale in the NevoLine upstream platform (Univercells Technologies). The NevoLine platform incorporates the scale-X structured fixed-bed bioreactor system.
